Discovery, characterization, and clinical development of the glucagon-like peptides

Daniel J Drucker, Joel F Habener, Jens Juul Holst

    109 Citationer (Scopus)
    67 Downloads (Pure)

    Abstract

    The discovery, characterization, and clinical development of glucagon-like-peptide-1 (GLP-1) spans more than 30 years and includes contributions from multiple investigators, science recognized by the 2017 Harrington Award Prize for Innovation in Medicine. Herein, we provide perspectives on the historical events and key experimental findings establishing the biology of GLP-1 as an insulin-stimulating glucoregulatory hormone. Important attributes of GLP-1 action and enteroendocrine science are reviewed, with emphasis on mechanistic advances and clinical proof-of-concept studies. The discovery that GLP-2 promotes mucosal growth in the intestine is described, and key findings from both preclinical studies and the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed. Finally, we summarize recent progress in GLP biology, highlighting emerging concepts and scientific insights with translational relevance.

    OriginalsprogEngelsk
    TidsskriftThe Journal of Clinical Investigation
    Vol/bind127
    Udgave nummer12
    Sider (fra-til)4217-4227
    Antal sider11
    ISSN0021-9738
    DOI
    StatusUdgivet - 1 dec. 2017

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Discovery, characterization, and clinical development of the glucagon-like peptides'. Sammen danner de et unikt fingeraftryk.

    Citationsformater